Evidence map›Paper›PMID 35310379›Full record

ArticleBioactive materials2022

Nidogen1-enriched extracellular vesicles accelerate angiogenesis and bone regeneration by targeting Myosin-10 to regulate endothelial cell adhesion.

Pengzhen Cheng, Tianqing Cao, Xueyi Zhao, Weiguang Lu, Sheng Miao, Fenru Ning, Dong Wang, Yi Gao, Long Wang, Guoxian Pei and 1 more

Open access · goldAbstract read
In one paragraph

Article in Bioactive materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Pengzhen ChengDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Tianqing CaoDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Xueyi ZhaoCollege of Life Sciences, Northwest University, Xi'an, 710069, China.
Weiguang LuDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Sheng MiaoDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Fenru NingDepartment of Neonatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Dong WangDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Yi GaoDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Long WangDepartment of Orthopaedics, Chinese PLA General Hospital, Beijing, 100853, China.
Guoxian PeiDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Liu YangDepartment of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Xijing Hospital · CNNorthwest University · CNChinese PLA General Hospital · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The technique bottleneck of repairing large bone defects with tissue engineered bone is the vascularization of tissue engineered grafts. Although some studies have shown that extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (BMSCs) promote bone healing and repair by accelerating angiogenesis, the effector molecules and the mechanism remain unclear, which fail to provide ideas for the future research and development of cell-free interventions. Here, we found that Nidogen1-enriched EV (EV-NID1) derived from BMSCs interferes with the formation and assembly of focal adhesions (FAs) by targeting myosin-10, thereby reducing the adhesion strength of rat arterial endothelial cells (RAECs) to the extracellular matrix (ECM), and enhancing the migration and angiogenesis potential of RAECs. Moreover, by delivery with composite hydrogel, EV-NID1 is demonstrated to promote angiogenesis and bone regeneration in rat femoral defects. This study identifies the intracellular binding target of EV-NID1 and further elucidates a novel approach and mechanism, thereby providing a cell-free construction strategy with precise targets for the development of vascularized tissue engineering products.

Indexed as

AngiogenesisBone tissue engineeringExtracellular vesiclesHydrogelNidogen1

Identifiers

PMID35310379
PMCPMC8897190
OpenAlexW3210417739

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.